Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1.
Corbett JW, Ko SS, Rodgers JD, Jeffrey S, Bacheler LT, Klabe RM, Diamond S, Lai CM, Rabel SR, Saye JA, Adams SP, Trainor GL, Anderson PS, Erickson-Viitanen SK. Corbett JW, et al. Among authors: jeffrey s. Antimicrob Agents Chemother. 1999 Dec;43(12):2893-7. doi: 10.1128/AAC.43.12.2893. Antimicrob Agents Chemother. 1999. PMID: 10582878 Free PMC article.
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C. Bacheler L, et al. Among authors: jeffrey s. J Virol. 2001 Jun;75(11):4999-5008. doi: 10.1128/JVI.75.11.4999-5008.2001. J Virol. 2001. PMID: 11333879 Free PMC article.
DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.
Kaltenbach RF 3rd, Trainor G, Getman D, Harris G, Garber S, Cordova B, Bacheler L, Jeffrey S, Logue K, Cawood P, Klabe R, Diamond S, Davies M, Saye J, Jona J, Erickson-Viitanen S. Kaltenbach RF 3rd, et al. Among authors: jeffrey s. Antimicrob Agents Chemother. 2001 Nov;45(11):3021-8. doi: 10.1128/AAC.45.11.3021-3028.2001. Antimicrob Agents Chemother. 2001. PMID: 11600351 Free PMC article.
Structure-activity relationships of tubulysin analogues.
Courter JR, Hamilton JZ, Hendrick NR, Zaval M, Waight AB, Lyon RP, Senter PD, Jeffrey SC, Burke PJ. Courter JR, et al. Bioorg Med Chem Lett. 2020 Jul 15;30(14):127241. doi: 10.1016/j.bmcl.2020.127241. Epub 2020 May 5. Bioorg Med Chem Lett. 2020. PMID: 32527543
Dipeptide-based highly potent doxorubicin antibody conjugates.
Jeffrey SC, Nguyen MT, Andreyka JB, Meyer DL, Doronina SO, Senter PD. Jeffrey SC, et al. Bioorg Med Chem Lett. 2006 Jan 15;16(2):358-62. doi: 10.1016/j.bmcl.2005.09.081. Epub 2005 Nov 3. Bioorg Med Chem Lett. 2006. PMID: 16275070
249 results